Accrufer® New Drug Submission accepted by Health Canada
Xpediator PLC (XPD.L) Trading Update
Xpediator (AIM: XPD), a leading provider of freight management services across the UK and Central and Eastern Europe, is pleased to confirm that, further to the AGM Statement of 8
Shield Therapeutics (STX.L) US launch of Accrufer® confirmed for July 1, 2021
London, UK, June 24, 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), confirms
Shield Therapeutics (STX.L) USA Deal
Shield confirms it remains on track to launch Accrufer® in the US by end of June 2021